Hims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...

Hims & Hers cofounder and CEO Andrew Dudum dropped out of Forbes’ billionaire ranks on Monday – less than two months after joining the three-comma-club, in May. Dudum, 36, lost more than $400 ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership.

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...